Core Scientific enters the week of August 6 earnings with a paradox at its centre: short sellers have meaningfully reduced their exposure while analysts are simultaneously lifting price targets — yet the stock has still shed 14% over the past week and 24% over the past month.
The analyst move is the most immediate catalyst. Three firms raised targets on July 29 alone. Macquarie lifted to $38, Needham moved to $35 from $29, and Canaccord Genuity went to $36 from $30 — all maintaining Buy or Outperform ratings. BTIG reiterated its Buy at $38 the day before. The consensus mean target now sits near $35.86 against a current price of $20.75, implying roughly 73% upside on the Street's central case. That gap is wide enough to be notable, not suspicious — it reflects genuine analyst conviction in CORZ's pivot toward AI and HPC colocation, not a data artefact. The unanimity of direction is striking: every recent action is a raise or a reiterate, with no downgrades in the recent record.
Short positioning tells a less crowded story than the headline number implies. SI at 20.3% of free float remains elevated in absolute terms, but the trend is clearly lower — shorts fell roughly 9.5% over the week after a more dramatic drop on July 23-24, when short shares declined by nearly 7 million in a single session. That step-down suggests active covering rather than gradual attrition. Borrow conditions confirm the retreat: cost to borrow has collapsed to 0.30%, down more than 50% on the week and the lowest level in the 30-day history shown. Availability has loosened to around 212% — well above the tight conditions that characterised the 52-week minimum of 0.4% — meaning there is ample supply for new shorts to enter if the narrative turns. The ORTEX short score, running near 67, has drifted lower all week from a recent high above 68, consistent with that unwinding. The EPS surprise factor score, sitting at the 100th percentile, suggests the covering may be pre-emptive ahead of the August 6 print.
Options activity has edged slightly more defensive, though not dramatically so. The put/call ratio moved to 0.50 on Tuesday, a touch above its 20-day average near 0.48 and roughly one standard deviation elevated. The 52-week PCR range runs from 0.24 to 0.63, so the current reading is far from extreme — this is mild caution, not hedging in size. The options market is not yet pricing a large binary move for the August 6 earnings.
The two prior results with price-reaction data paint an uneven picture. The May 2026 earnings triggered a 4.6% single-day gain but gave back most of that over five sessions. The February 2026 print moved the stock down 6.9% on the day, then recovered 1.2% over the following week. Neither reaction was large by the standards of a name with 20% short interest. Peers have had a bruising week: WULF fell 14%, IREN dropped 18%, and NBIS lost 22%. RIOT, by contrast, held relatively firm at -1.2%. CORZ's -14% sits in the middle of that range — weak, but not the sector's worst.
The insider picture adds one cautionary note. CEO Adam Sullivan sold 15,584 shares on July 16, following a larger sale on June 30. The Chief Legal Officer has been selling in regular tranches across the same period. Net insider flow over 90 days is a small positive in share terms but reflects purchases elsewhere in the record, not recent buying — the last several weeks have been uniformly seller-side. None of these sales are individually large enough to be alarming, and routine scheduled selling is a plausible explanation, but the pattern runs counter to the bullish analyst posture.
The August 6 earnings report will test whether the analyst target upgrades — concentrated on the HPC/AI colocation opportunity and the CRWV contract — have been validated by actual revenue progress, or whether the stock's month-long decline already anticipates a softer print.
See the live data behind this article on ORTEX.
Open CORZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
